β遮断薬市場：タイプ、用途、流通チャネル別-2024-2030年の世界予測

β遮断薬市場規模は2023年に105億4,000万米ドルと推計され、2024年には110億6,000万米ドルに達し、CAGR 5.23%で2030年には150億8,000万米ドルに達すると予測されています。

β遮断薬は、科学的にはβ-アドレナリン遮断薬としても知られ、様々な心血管系疾患を管理するために処方される薬の一種です。その主な機能は、体内のβ受容体に対するアドレナリン（ホルモンおよび神経伝達物質）の作用をブロックすることです。この作用は心臓を落ち着かせる効果があり、心臓の拍動をよりゆっくり、より少ない力で行わせるため、血圧を下げるのに役立ちます。さらに、β遮断薬は静脈や動脈の血流を改善します。これらの薬剤は、高血圧、狭心症（胸の痛み）、心不全、不整脈（不整脈）の治療に一般的に使用され、場合によっては片頭痛の予防にも使用されます。高齢化や食生活の乱れ、運動不足、喫煙などの生活習慣に起因する心血管疾患の世界の増加は、β遮断薬の需要を促進しています。しかしながら、β遮断薬に関連する疲労、体重増加、四肢の冷えなどの副作用は、特定の患者集団における使用を制限する可能性があります。一方、特定の病状を持つ患者に対応した、副作用の少ない新規のβ遮断薬の開発は、主要なプレーヤーに重要な道を提示しています。さらに、個別化された患者ケアと投薬管理のためのデジタルヘルス技術の統合は、革新的なソリューションの機会を提供します。

タイプ呼吸器疾患への対処を目的としたβ1選択的拮抗薬の消費拡大

β遮断薬は、心拍数を低下させることで心臓の仕事量を減らし、血圧を下げることで様々な心血管系疾患の管理に広く使用されている薬です。ラベタロール、硫酸ペンブトロール、ピンドロール、塩酸ソタロールなどのβ非選択的遮断薬は、心臓や体の他の部分にあるβ1受容体とβ2受容体の両方に影響を与えます。これらの薬は汎用性があり、高血圧からある種の不整脈まで対応できます。一方、Acebutolol、Atenolol、Bisoprolol、Metoprololなどのβ-1選択的遮断薬は、主に心臓に存在するβ-1受容体を標的とします。その選択性により、肺に影響を及ぼすリスクを最小限に抑えることができるため、呼吸器に不安を抱える患者には好ましい選択肢となります。これらの違いを理解することは、これらの薬剤を処方する際にヘルスケア専門家にとって極めて重要であり、患者が健康状態に応じた適切な治療を受けられるようにします。

アプリケーション様々な心血管系疾患の管理におけるアドレナリンとしてのβ遮断薬の使用量の増加

β遮断薬は、心臓や血管の特定のシグナルを遮断し、心拍数、血圧、心臓への負担を減少させる能力があるため、様々な心臓疾患やその他の健康問題の管理に広く使用されている薬剤の一種です。心疾患では、狭心症（胸痛）の治療の基礎となり、発作の頻度と重症度の軽減に役立ちます。また、心房細動の管理にも極めて重要であり、心拍数とリズムをコントロールすることで、脳卒中や心臓関連の合併症のリスクを軽減することに貢献します。心不全の場合、β遮断薬は心臓の負担を軽減し、有害な心臓のリズムを抑制することにより、心臓の機能を改善し、生存率を高めることができます。β遮断薬は、心臓に関連する疾患以外にも、緑内障の治療にも重要な役割を果たしています。緑内障は、眼圧の上昇を特徴とする疾患で、視力低下を引き起こします。さらに、β遮断薬は高血圧の基礎治療薬であり、血圧を効果的に下げることで、心臓病や脳卒中の発症リスクを下げます。β遮断薬は、様々な疾患への多面的な応用を通じて、様々な疾患に対する治療薬の重要な構成要素であり続けており、その能力は、罹患患者の生活の質と生存率を改善することで強調されています。

地域別の洞察

米国、特に米国とカナダでは、心血管疾患（CVDs）の高い有病率と高齢化により、β遮断薬の需要は依然として大きいです。米国では、ジェネリック医薬品のイントロダクションが着実に進んでいるため、これらの医薬品は幅広い層にとってより入手しやすく、手頃な価格となっています。また、循環器系の健康に焦点を当てた健康への取り組みや意識向上プログラムも、患者への働きかけを強めています。カナダも同様の動向で、これらの医薬品へのアクセスを支える強固なヘルスケアシステムを有しています。EMEAでは、ヘルスケア政策がβ遮断薬への幅広いアクセスを保証しています。この地域の需要は安定しており、高品質で革新的な循環器治療薬が中心となっています。ジェネリック医薬品の採用は国によって異なり、ヘルスケアシステムのニュアンスや患者の認識にも影響されます。さらに、アジア太平洋地域ではβ遮断薬市場が急成長しています。中国では心血管疾患の罹患率が増加しており、ヘルスケアインフラを改善するための政府の取り組みがβ遮断薬の需要を促進しています。日本市場の特徴は、高度なヘルスケア技術と、持続的な心血管治療を必要とする高齢者人口です。インドは、意識の高まりと医療サービスへのアクセスの改善により、需要が急増しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはβ遮断薬市場の評価において極めて重要です。事業戦略や製品満足度に関する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、β遮断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.β遮断薬市場の市場規模および予測は？

2.β遮断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.β遮断薬市場の技術動向と規制枠組みは？

4.β遮断薬市場における主要ベンダーの市場シェアは？

5.β遮断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化が進むと心臓関連疾患にかかりやすくなる
    • うっ血性心不全、不整脈、甲状腺機能亢進症の管理におけるβ遮断薬の役割の増大
    • 政府やヘルスケア機関による公衆衛生の取り組みと啓発プログラム
  • 抑制要因
    • 製品リコールの発生率
  • 機会
    • 高血圧に対する個別化β遮断薬治療の開発に向けた研究開発（R&D）活動の拡大
    • β遮断薬の分析手法における新たな動向
  • 課題
    • β遮断薬の摂取に伴う副作用
• 市場セグメンテーション分析
  • タイプ：呼吸器疾患の懸念に対処するためのβ1選択的遮断薬の消費量の増加
  • 応用：さまざまな心血管疾患の管理におけるアドレナリンとしてのβ遮断薬の使用増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 β遮断薬市場：タイプ別

• ベータ非選択的遮断薬
• ベータ1選択的遮断薬

第7章 β遮断薬市場：用途別

• 心臓疾患
• 緑内障
• 高血圧

第8章 β遮断薬市場：流通チャネル別

• 病院薬局
• 小売薬局

第9章 南北アメリカのβ遮断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のβ遮断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのβ遮断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDAが活動性潰瘍性大腸炎の治療薬VELSIPITYを承認
  • 「新しい超短時間作用型ベータ遮断薬ランジオロールが、カナダで重篤な心臓疾患の治療薬として承認されました」
  • アジャンタファーマ、高血圧症をシンプルかつ効果的に管理できる新しい二重作用タブレット「Met-XL AMT」を発売
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BETA BLOCKERS MARKET RESEARCH PROCESS
• FIGURE 2. BETA BLOCKERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BETA BLOCKERS MARKET DYNAMICS
• FIGURE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BETA BLOCKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BETA BLOCKERS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BETA BLOCKERS MARKET SIZE, BY LABETALOL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BETA BLOCKERS MARKET SIZE, BY LABETALOL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BETA BLOCKERS MARKET SIZE, BY PENBUTOLOL SULFATE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BETA BLOCKERS MARKET SIZE, BY PENBUTOLOL SULFATE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BETA BLOCKERS MARKET SIZE, BY PINDOLOL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BETA BLOCKERS MARKET SIZE, BY PINDOLOL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BETA BLOCKERS MARKET SIZE, BY SOTALOL HYDROCHLORIDE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BETA BLOCKERS MARKET SIZE, BY SOTALOL HYDROCHLORIDE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BETA BLOCKERS MARKET SIZE, BY ACEBUTOLOL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BETA BLOCKERS MARKET SIZE, BY ACEBUTOLOL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATENOLOL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL BETA BLOCKERS MARKET SIZE, BY BISOPROLOL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL BETA BLOCKERS MARKET SIZE, BY BISOPROLOL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL BETA BLOCKERS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL BETA BLOCKERS MARKET SIZE, BY METOPROLOL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL BETA BLOCKERS MARKET SIZE, BY ANGINA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL BETA BLOCKERS MARKET SIZE, BY ANGINA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL BETA BLOCKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL BETA BLOCKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL BETA BLOCKERS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL BETA BLOCKERS MARKET SIZE, BY GLAUCOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL BETA BLOCKERS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL BETA BLOCKERS MARKET SIZE, BY HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL BETA BLOCKERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL BETA BLOCKERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL BETA BLOCKERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL BETA BLOCKERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. AMERICAS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 56. AMERICAS BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 73. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 74. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 75. ARGENTINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. ARGENTINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. ARGENTINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 78. ARGENTINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 81. BRAZIL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 82. BRAZIL BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 83. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 84. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 85. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 86. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 87. BRAZIL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. BRAZIL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. BRAZIL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 90. BRAZIL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 93. CANADA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 94. CANADA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 95. CANADA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 96. CANADA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 97. CANADA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 98. CANADA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 99. CANADA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. CANADA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. CANADA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 102. CANADA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 103. CANADA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 104. CANADA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 105. MEXICO BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 106. MEXICO BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 107. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 108. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 109. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 110. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 111. MEXICO BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. MEXICO BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. MEXICO BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 114. MEXICO BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 117. UNITED STATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 118. UNITED STATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 119. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 120. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 121. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 122. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 123. UNITED STATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. UNITED STATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. UNITED STATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 126. UNITED STATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 132. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 134. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 136. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 138. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 139. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 140. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 145. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 146. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 147. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 148. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 149. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 150. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 151. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 154. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 157. CHINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 158. CHINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 159. CHINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 160. CHINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 161. CHINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 162. CHINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 163. CHINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. CHINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. CHINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 166. CHINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 167. CHINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 168. CHINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 169. INDIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 170. INDIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 171. INDIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 172. INDIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 173. INDIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 174. INDIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 175. INDIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. INDIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. INDIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 178. INDIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 179. INDIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 180. INDIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 181. INDONESIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 182. INDONESIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 183. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 184. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 185. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 186. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 187. INDONESIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. INDONESIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. INDONESIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 190. INDONESIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 193. JAPAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 194. JAPAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 195. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 196. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 197. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 198. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 199. JAPAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. JAPAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. JAPAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 202. JAPAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 205. MALAYSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 206. MALAYSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 207. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 208. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 209. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 210. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 211. MALAYSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 212. MALAYSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 213. MALAYSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 214. MALAYSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 217. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 218. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 219. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 220. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 221. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 222. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 223. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 224. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 225. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 226. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 229. SINGAPORE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 230. SINGAPORE BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 231. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 232. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 233. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 234. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 235. SINGAPORE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 236. SINGAPORE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 237. SINGAPORE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 238. SINGAPORE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 241. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 242. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 249. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 250. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 253. TAIWAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 254. TAIWAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 255. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 256. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 257. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 258. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 259. TAIWAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 260. TAIWAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 261. TAIWAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 262. TAIWAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 265. THAILAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 266. THAILAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 267. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 268. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 269. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 270. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 271. THAILAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 272. THAILAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 273. THAILAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 274. THAILAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 277. VIETNAM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. VIETNAM BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 280. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 281. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 282. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 283. VIETNAM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 284. VIETNAM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 285. VIETNAM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 286. VIETNAM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 287. VIETNAM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 288. VIETNAM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 303. DENMARK BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 304. DENMARK BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 305. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 306. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 307. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 308. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 309. DENMARK BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 310. DENMARK BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 311. DENMARK BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 312. DENMARK BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 313. DENMARK BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 314. DENMARK BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 315. EGYPT BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 316. EGYPT BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 317. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 318. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 319. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 320. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 321. EGYPT BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 322. EGYPT BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 323. EGYPT BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 324. EGYPT BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 325. EGYPT BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 326. EGYPT BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 327. FINLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 328. FINLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 329. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 330. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 331. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 332. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 333. FINLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 334. FINLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 335. FINLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 336. FINLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 337. FINLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 338. FINLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 339. FRANCE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 340. FRANCE BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 341. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 342. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 343. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2023 (USD MILLION)
• TABLE 344. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2024-2030 (USD MILLION)
• TABLE 345. FRANCE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 346. FRANCE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 347. FRANCE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2023 (USD MILLION)
• TABLE 348. FRANCE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2024-2030 (USD MILLION)
• TABLE 349. FRANCE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 350. FRANCE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 351. GERMANY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 352. GERMANY BETA BLOCKERS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 353. GERMANY BET

[180 Pages Report] The Beta Blockers Market size was estimated at USD 10.54 billion in 2023 and expected to reach USD 11.06 billion in 2024, at a CAGR 5.23% to reach USD 15.08 billion by 2030.

Beta blockers, also known scientifically as beta-adrenergic blocking agents, are a class of medications prescribed for managing various cardiovascular conditions. Their primary function is to block the effects of adrenaline (a hormone and neurotransmitter) on the body's beta receptors. This action has a calming effect on the heart, causing it to beat more slowly and with less force, which helps to reduce blood pressure. In addition, beta blockers improve blood flow through veins and arteries. These medications are commonly used in the treatment of high blood pressure, angina (chest pain), heart failure, arrhythmias (irregular heartbeat), and, in some cases, for the prevention of migraine headaches. The rising prevalence of cardiovascular diseases globally, fueled by aging populations and lifestyle factors such as poor diet, physical inactivity, and smoking, propels the demand for beta blockers. However, side effects associated with beta blockers, such as fatigue, weight gain, and cold extremities, may limit their use in certain patient populations. Meanwhile, the development of novel beta blockers with fewer side effects, catering to patients with specific medical conditions, presents significant avenues for the key players. In addition, integrating digital health technologies for personalized patient care and medication management offers opportunities for innovative solutions.

Type: Rising consumption of beta-1 selective blockers to address respiratory concerns

Beta blockers are a medication widely used to manage various cardiovascular conditions by slowing down the heart rate, thus reducing the heart's workload and helping to lower blood pressure. Beta non-selective blockers, including Labetalol, Penbutolol Sulfate, Pindolol, and Sotalol Hydrochloride, impact both beta-1 and beta-2 receptors in the heart and other parts of the body. These medications are versatile, addressing conditions from hypertension to certain types of irregular heartbeat. On the other hand, Beta-1 selective blockers, such as Acebutolol, Atenolol, Bisoprolol, and Metoprolol, primarily target the beta-1 receptors present in the heart. Their selectivity makes them a preferred choice for patients with respiratory concerns, as they minimize the risk of affecting the lungs. Understanding these differences is crucial for healthcare professionals while prescribing these medications, ensuring patients receive the appropriate treatment for their health condition.

Application: Increasing usage of beta blockers as an adrenaline in managing various cardiovascular conditions

Beta blockers represent a class of medication widely employed in managing various cardiac conditions and other health issues due to their ability to block specific signals in the heart and blood vessels, decreasing heart rate, blood pressure, and strain on the heart. In cardiac diseases, they are foundational in treating angina (chest pain), helping to reduce the frequency and severity of episodes. They are also crucial in managing atrial fibrillation, contributing to controlling heart rhythm and rate, thereby mitigating the risk of stroke and heart-related complications. In the context of heart failure, beta blockers can improve heart function and enhance survival rates by easing the heart's workload and inhibiting harmful heart rhythms. Beyond heart-related conditions, beta blockers play a significant role in treating glaucoma, a condition characterized by increased pressure in the eye, which causes vision loss. Additionally, they are a cornerstone therapy for hypertension (high blood pressure), effectively lowering blood pressure levels, which, in turn, reduces the risk of developing heart disease and stroke. Through their multifaceted application across a spectrum of diseases, beta blockers remain a vital component in the therapeutic arsenal against various ailments, underscored by their ability to improve the quality of life and survival among afflicted patients.

Regional Insights

In America, particularly the United States and Canada, the demand for beta blockers remains significant, propelled by a high prevalence of cardiovascular diseases (CVDs) and an aging population. The United States has seen a steady introduction of generic versions, which has made these medications more accessible and affordable to a broad segment of the population. Health initiatives and awareness programs focusing on cardiovascular health have also increased patient outreach. Canada follows a similar trend with a robust healthcare system supporting access to these medications. In EMEA, healthcare policies ensure a wide accessibility to beta blockers. This region's demand is stable, focusing on high-quality and innovative cardiovascular treatments. The adoption of generic drugs varies by country and is influenced by healthcare system nuances and patient perceptions. Moreover, the Asia Pacific region is experiencing rapid growth in the beta blockers market. The increasing incidence of cardiovascular diseases in China and government initiatives to improve healthcare infrastructure drive demand for beta blockers. Japan's market is characterized by advanced healthcare technologies and an elderly population that requires sustained cardiovascular care. India is witnessing a surge in demand due to rising awareness and improving access to healthcare services.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Beta Blockers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Beta Blockers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Beta Blockers Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, Amneal Pharmaceuticals LLC, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., Neuracle Lifesciences Private Limited, Novartis AG, Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Menarini Group, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Beta Blockers Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Beta Non-selective Blocker
    • Labetalol
    • Penbutolol Sulfate
    • Pindolol
    • Sotalol Hydrochloride

• Beta-1 Selective Blocker
  • Acebutolol
  • Atenolol
  • Bisoprolol
  • Metoprolol
• Application
  • Cardiac Diseases
    • Angina
    • Atrial Fibrillation
    • Heart Failure

• Glaucoma
• Hypertension

• Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Beta Blockers Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Beta Blockers Market?

3. What are the technology trends and regulatory frameworks in the Beta Blockers Market?

4. What is the market share of the leading vendors in the Beta Blockers Market?

5. Which modes and strategic moves are suitable for entering the Beta Blockers Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising aging population more susceptible to heart-related conditions
    • 5.1.1.2. Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
    • 5.1.1.3. Public health initiatives and awareness programs by governments and healthcare organizations
  • 5.1.2. Restraints
    • 5.1.2.1. Incidence of product recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
    • 5.1.3.2. Novel trends in analytical methods for beta blockers
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with the consumption of beta blockers
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising consumption of beta-1 selective blockers to address respiratory concerns
  • 5.2.2. Application: Increasing usage of beta blockers as an adrenaline in managing various cardiovascular conditions
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Beta Blockers Market, by Type

• 6.1. Introduction
• 6.2. Beta Non-selective Blocker
• 6.3. Beta-1 Selective Blocker

7. Beta Blockers Market, by Application

• 7.1. Introduction
• 7.2. Cardiac Diseases
• 7.3. Glaucoma
• 7.4. Hypertension

8. Beta Blockers Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies

9. Americas Beta Blockers Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Beta Blockers Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Beta Blockers Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Approved VELSIPITY, An Advancement To Treat Active Ulcerative Colitis
  • 12.3.2. "New Ultra-Short-Acting Beta Blocker, Landiolol, Received Canadian Approval For Critical Care Cardiac Conditions
  • 12.3.3. Ajanta Pharma Launched Met-XL AMT, A New Dual-Action Tablet for Simplified and Effective Hypertension Management
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio